Gilead Wins Supreme Court Ruling On Drug Safety Duty

California's Supreme Court has declared that drug companies are not legally obligated to develop medications that are even safer than their existing, approved products. The ruling, issued on August 3, 2026, in favor of Gilead Sciences, dismissed negligence claims brought by approximately 24,000 patients who used a Gilead HIV drug.

These patients alleged that Gilead should have developed an alternative drug with fewer side effects sooner. The court's majority opinion stated that imposing a "duty to innovate" would lead juries to second-guess complex scientific judgments and could negatively impact pharmaceutical innovation, public health, and patient safety.

The case had the potential to significantly alter product liability law for the pharmaceutical sector. Many industry groups and major drug manufacturers supported Gilead's appeal, arguing that such a duty would increase development costs and potentially slow the release of needed treatments.

However, in a dissenting opinion, Justice Kelli Evans characterized Gilead's conduct as "morally blameworthy." She suggested the drug industry already benefits from special protections and urged the legislature to reconsider immunity from negligence claims.